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lanwpc.2021.100353Since the COVID-19 pandemic started in 2020, health-
care workers (HCW) and other hospital personnel have
been regarded as “frontliners”, and at increased risk of
SARS-CoV-2 infection compared to the general popula-
tion. As such, testing only symptomatic individuals or
regular testing of HCWs who directly attend to COVID-
19 patients or specimens may underestimate the extent
of infection, and actual SARS-CoV-2 seroprevalence.
Because of this, the World Health Organization has
called for seroepidemiological surveys to assess the
extent of infection amongst HCW and other popula-
tions to provide timely estimates of COVID-19 virus
infection severity and inform public health responses
and evidence-based policy decisions.1
We are conducting a longitudinal SARS-CoV-2
seroepidemiological investigation among employees of
San Lazaro Hospital (SLH), a tertiary infectious disease
referral hospital in Manila, Philippines. Here, we report
the first phase of the study and the first estimates of
SARS-CoV-2 seroprevalence amongst HCW in the Phil-
ippines. From March 8 to April 24, 2021, we invited all
HCW (around »1,200) in the hospital to be part of the
study. We obtained blood samples for WANTAI SARS-
CoV-2 Ab ELISA testing2 (see supplementary material)
and basic demographic data (name, age and sex) prior
to COVID-19 vaccination roll-out from 525 hospital
employees. Amongst them, »60% of participants pro-
vided additional data on sociodemographic and clinicalAbbreviation: HCW, healthcare worker; SLH, San Lazaro
Hospital
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www.thelancet.com Vol 18 Month January, 2022characteristics by answering and returning a question-
naire after the blood draw.
One hundred seventy eight HCWs (34%) were sero-
positive with an adjusted seroprevalence of 36% (95%
CI: 30¢0 - 38¢1) using the Rogan and Gladen formula to
account for the serological test sensitivity and specific-
ity.3 Differences in seropositivity HCWs were observed
in different categories of education (p=0¢006), house-
hold monthly income (p=0¢001), occupation
(p=0.009), and individuals with or without a history of
previous confirmed COVID-19 infection (p<0¢001)
(Table 1). Healthcare support service staff (i.e. catering
staff, janitorial service personnel, admission/recep-
tionist clerks, drivers and security personnel) had
increased odds of seropositivity compared with nurses
(crude odds ratio [OR] 3.10, 95% CI 1.59-6.05, p-
value=0.001), although statistical significance was lost
after adjusting for age, income and education. HCWs
in the highest income group had reduced odds of sero-
positivity (AOR 0.43, 95% CI 0.21 - 0.91, p-
value=0.026) compared to the middle-income groups
(Figure 1). The majority of the healthcare support ser-
vice staff belonged to middle or low-income house-
holds. Our findings contrast with seroprevalence
studies among HCWs in developed countries, where
seroprevalence among those who had patient contacts
were higher.4,5 However, in our study it was not possi-
ble to determine whether infection was acquired inside
or outside of the hospital.
We acknowledge some limitations to our analysis.
Firstly, this is only a single-center study. Hence, we
recommend that similar seroprevalence studies be con-
ducted in different healthcare settings in the country.
Secondly, in our study it was not possible to determine
whether infection was acquired inside or outside of the
hospital. Thirdly, certain occupations and male sex
were predictors of missing data (i.e. less likely to return1
Comment
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the questionnaire). Finally, it is possible that our
results presented in Table 1 may have been confounded
with the effects of the missing data.
The findings in our study helped identify the non-
clinical support service staff belonging to lower income
households as having the highest risk for COVID-19
infection among the healthcare workforce. Their socio-
economic background, compounded by their nature of
work, makes them the easiest target for COVID-19
infection. While it remains important to continue to
protect clinical HCWs as essential assets against
COVID-19, our findings provide a wake-up call to
realign hospital policies to extend provision of periodic
screening and hazard pay to these non-clinical front-
liners who play significant roles in fighting COVID-19
but may be perceived to have lesser risk in acquiring
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